How we build success
Medical innovations are precious and exciting and come from all over. Making a good idea in medicine into a product is a difficult and expensive process. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.
That’s where Greenfire comes in. We have assembled experts, advisors, service providers, and capital to deploy on late pre-clinical and early clinical assets to accelerate their development into products.
Our extensive network seeks out exciting innovations, engages flexibly with the innovators, and accelerates the transition to medical products. We take the unappreciated risks out of development – timely access to expertise and capital. If you think you have an innovation that fits our profile, contact us.
And when a product is ready for the last steps for approval and commercialization, our team has deep experience in navigating the right path to optimize success and return for all participants.
Our process sounds simple but execution is where we excel
Deploy very experienced biopharma team for efficient drug development and business management
Utilize a successful organizational model; leverage virtual operations focused program management and partner ecosystem of service providers
Exit programs after advancing candidates to an appropriate value inflection point
Provide excellent returns to investors by delivering superior products to patients
CEO and Founder, Director
CEO & President Nektar Therapeutics
VP and Gen Mgr Kodak’s Interactive Systems
VP Finance at TRW-Fujitsu
Steve Morris, MD
CEO & Internist/Medical Oncologist
Former PI: St Jude’s (discovered ALK, developed ALK CDx and inhibitors)
Michael Weickert, PhD
CEO at Pacylex, Sonescence, SEA Med., COO Therashock, drug development at Ligand, Nektar, Auspex, NIH / NCI
Sanjeev Munshi, PHD, MBA
SVP, BD & Alliance Management, InveniAI
Ex. Director Merck BD and Discovery
Executive Director, CMC
BOARD OF DIRECTORS
Purnanand Sarma, PhD
Chris Searcy, PharmD
VP Valeritas, Nektar, Pfizer
Making a fast start to building an innovative pipeline, agnostic to therapeutic areas, we are addressing serious unmet medical needs.
If you think you have an innovation that fits this portfolio, contact us.
Questions? We’ve got answers!
Greenfire Bio Announces Initiation of Phase 1 Clinical Trial of GRN-300, a SIK2 inhibitor, for Ovarian Cancer
Austin TX, January 15, 2021 -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio Inc., initiated a Phase 1 clinical trial of GRN-300, a first-in-class, orally bioavailable small molecule inhibitor of the Salt Inducible Kinases 2 and 3 (SIK2, SIK3), at the University of Texas MD...
Austin TX, December 16, 2020 -- Greenfire Bio, LLC announced today that it has completed its first transaction, the acquisition of a first-in-class, orally bioavailable small molecule dual inhibitor of the Salt Inducible Kinases 2 and 3 (SIK2, SIK3) for ovarian cancer. Greenfire Bio, LLC has...